Literature DB >> 18378786

Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?

G B Migliori, C Lange, E Girardi, R Centis, G Besozzi, K Kliiman, L R Codecasa, A Spanevello, D M Cirillo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18378786     DOI： 10.1183/09031936.00159807

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  13 in total

1.  Outcome of hospitalized MDR-TB patients: Israel 2000-2005.

Authors:  D Bendayan; A Hendler; V Polansky; M Weinberger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-10-23       Impact factor: 3.267

2.  Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects.

Authors:  Ekaterina V Kurbatova; Allison Taylor; Victoria M Gammino; Jaime Bayona; Mercedes Becerra; Manfred Danilovitz; Dennis Falzon; Irina Gelmanova; Salmaan Keshavjee; Vaira Leimane; Carole D Mitnick; Ma Imelda Quelapio; Vija Riekstina; Piret Viiklepp; Matteo Zignol; J Peter Cegielski
Journal:  Tuberculosis (Edinb)       Date:  2012-07-10       Impact factor: 3.131

3.  Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.

Authors:  Kwok-Chiu Chang; Chi-Chiu Leung; Wing-Wai Yew; Eric Chung-Ching Leung; Wai-Man Leung; Cheuk-Ming Tam; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

4.  Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis.

Authors:  Emmanuel Chigutsa; Sandra Meredith; Lubbe Wiesner; Nesri Padayatchi; Joe Harding; Prashini Moodley; William R Mac Kenzie; Marc Weiner; Helen McIlleron; Carl M J Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

5.  Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.

Authors:  Tan N Doan; Pengxing Cao; Theophilus I Emeto; James M McCaw; Emma S McBryde
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 6.  Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones.

Authors:  Giovanni Battista Migliori; Miranda W Langendam; Lia D'Ambrosio; Rosella Centis; Francesco Blasi; Emma Huitric; Davide Manissero; Marieke J van der Werf
Journal:  Eur Respir J       Date:  2012-05-31       Impact factor: 16.671

7.  Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience.

Authors:  Cui Hua Liu; Ling Li; Zhi Chen; Qi Wang; Yong Liang Hu; Baoli Zhu; Patrick C Y Woo
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

Review 8.  New Antituberculosis Drugs: From Clinical Trial to Programmatic Use.

Authors:  Gina Gualano; Susanna Capone; Alberto Matteelli; Fabrizio Palmieri
Journal:  Infect Dis Rep       Date:  2016-06-24

9.  TBNET - Collaborative research on tuberculosis in Europe.

Authors:  C Giehl; C Lange; R Duarte; G Bothamley; C Gerlach; D M Cirillo; D Wagner; B Kampmann; D Goletti; T Juers; M Sester
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-12-11

10.  Multidrug- and extensively drug-resistant tuberculosis, Germany.

Authors:  Barbara Eker; Johannes Ortmann; Giovanni B Migliori; Giovanni Sotgiu; Ralf Muetterlein; Rosella Centis; Harald Hoffmann; Detlef Kirsten; Tom Schaberg; Sabine Ruesch-Gerdes; Christoph Lange
Journal:  Emerg Infect Dis       Date:  2008-11       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.